The IRMA Community
Newsletters
Research IRM
Click a keyword to search titles using our InfoSci-OnDemand powered search:
|
Pharmacogenomics and Perinatal Morbidity: A Comprehensive Review of Bacterial Sexually Transmitted Infections
|
|
Author(s): Ioulia Magaliou (School of Health Sciences, University of Western Macedonia, Kozani, Greece), Georgios Michail (Faculty of Medicine, School of Health Sciences, University of Patras, Greece), Dimitrios Papoutsis (School of Health Sciences, University of Western Macedonia, Kozani, Greece), Nikoletta Daponte (Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece), Theoni Truva (School of Health Sciences, University of Western Macedonia, Kozani, Greece), Abraham Pouliakis (School of Medicine, National and Kapodistrian University of Athens, Athens, Greece), Alexandros Daponte (Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece)and George Valasoulis (Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece)
Copyright: 2025
Pages: 34
Source title:
Convergence of Population Health Management, Pharmacogenomics, and Patient-Centered Care
Source Author(s)/Editor(s): Anastasius S. Moumtzoglou (P & A Kyriakou Children's Hospital, Greece)
DOI: 10.4018/979-8-3693-3260-3.ch010
Purchase
|
Abstract
Sexually transmitted infections affecting young women of reproductive age, adolescents and children can cause a wide spectrum of long-term morbidities. During gestation, STIs can result in adverse pregnancy outcomes, emphasizing the importance of screening and early treatment. Perinatal STIs outbreaks exert significant impact on neonatal outcomes. The range of bacterial STIs encompasses common pathogens (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma hominis & genitalium, Ureaplasma infection, Treponema pallidum) and several less frequent species (Haemophilus ducreyi, Klebsiella granulomatis, etc). Nucleic acid amplification tests (NAATs), are more sensitive in the detection of bacterial loads and currently represent the gold standard tests. Overall, effectively managing bacterial STIs during pregnancy requires a population health approach that considers the specific needs of pregnant women, incorporates pharmacogenomic insights into treatment strategies, and prioritizes patient-centered care to ensure the best possible outcomes for both mothers and their newborns.
Related Content
|
Muhammad Farooq Umer.
© 2026.
28 pages.
|
|
Awesh Khati, Anindita Das, Debajit Karmakar.
© 2026.
26 pages.
|
|
Minhaj Ahmed Qidwai, Mohammad Kabir Gawhari.
© 2026.
20 pages.
|
|
Fozia Asif, Minhaj Ahmed Qidwai.
© 2026.
14 pages.
|
|
Saurabh Chandra, Bhupinder Singh.
© 2026.
20 pages.
|
|
Anshika Tyagi, Vishal Jain.
© 2026.
26 pages.
|
|
Saleema Gulzar, Samina Subzali Vertejee, Tazeen Saeed Ali, Rozina Karmaliani.
© 2026.
16 pages.
|
|
|